CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Syndivia is developing a platform for targeted cancer therapies using small molecule prodrugs that minimize off-target toxicity. Their lead product, SDV1001, shows promise in treating pancreatic cancer with high efficacy and minimal side effects.
The optimal potential of chemotherapy, despite being the standard treatment, has not yet been achieved and instead it can lead to adverse toxicological effects as a result of off-target toxicity, as the drug cannot discriminate between healthy and cancerous cells.
Small molecule prodrugs help solve this issue thanks to their high efficiency in targeting tumour cells.
Syndivia have developed the next-generation Antibody Drug Conjugation platform for development of highly effective small molecule…
SYNDIVIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
